We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 RELATED KIDNEY DAMAGE

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04706325
Recruitment Status : Unknown
Verified January 2021 by Aki̇f Şahi̇n, Kocaeli Derince Education and Research Hospital.
Recruitment status was:  Recruiting
First Posted : January 12, 2021
Last Update Posted : January 12, 2021
Sponsor:
Information provided by (Responsible Party):
Aki̇f Şahi̇n, Kocaeli Derince Education and Research Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
In this study, we investigate whether the early detection of risk factors in Covid-19 associated acute kidney injury contributes to us in the early initiation of treatment. We predict that if acute kidney damage is detected early in patients with early risk factors, permanent kidney damage will be seen less. In addition, we think that covid-19 patients may have positive contributions to shortening treatment time and reducing treatment costs. In addition, we are investigating whether it has a positive effect on patients' survival. In other words, we are investigating the contribution of risk factors to early diagnosis and treatment, the effect on health expenditures and mortality in patients with COVID-19 with acute kidney damage.

Condition or disease Intervention/treatment
Acute Kidney Injury Other: ACUTE KIDNEY INJURY

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Case-Control
Time Perspective: Prospective
Official Title: INVESTIGATION OF RISK FACTORS RELATED TO COVID-19 RELATED KIDNEY DAMAGE: A PROSPECTIVE OBSERVATIONAL STUDY
Estimated Study Start Date : January 1, 2021
Estimated Primary Completion Date : May 1, 2021
Estimated Study Completion Date : May 15, 2021

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
COVİD19 PCR (Polymerase Chain Reaction) AND CT POSITIVE
 Other: ACUTE KIDNEY INJURY
KDIGO LEVELS
COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
COVİD19 PCR (Polymerase Chain Reaction)NEGATİVE AND CT POSITIVE
 Other: ACUTE KIDNEY INJURY
KDIGO LEVELS
COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
COVİD19 PCR (Polymerase Chain Reaction) AND CT will be evaluated as NEGATIVE.
 Other: ACUTE KIDNEY INJURY
KDIGO LEVELS


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. KDIGO [ Time Frame: 4 MONTHS ]
    Kidney Disease: Improving Global Outcomes


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Over 18 aged

  • patients in ICU
Criteria

Inclusion Criteria:

  • Over 18 aged
  • patients in ICU

Exclusion Criteria:

  • Patients with known Chronic Renal Failure
  • who have received dialysis treatment before
  • who are under 18 years of age
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04706325


Contacts
Layout table for location contacts
Contact: mehmet yılmaz 05052174432 drmyilmaz33@gmail.com

Locations
Layout table for location information
Turkey
Akif Şahin Recruiting
Kocaeli, Turkey
Contact: mehmet yılmaz    05052174432    drmyilmaz33@gmail.com   
Sponsors and Collaborators
Kocaeli Derince Education and Research Hospital
Investigators
Layout table for investigator information
Principal Investigator: akif şahin kocaeli derh
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications of Results:
Aleebrahim-Dehkordi E, Reyhanian A, Saberianpour Sh, Hasanpour-Dehkordi A. Acute kidney injury in COVID-19; a review on current knowledge. J Nephropathol. 2020;9:e31. doi: 10.34172/jnp.2020.31

Layout table for additonal information
Responsible Party: Aki̇f Şahi̇n, md, Kocaeli Derince Education and Research Hospital
ClinicalTrials.gov Identifier: NCT04706325    
Other Study ID Numbers: kocaeli derh
First Posted: January 12, 2021    Key Record Dates
Last Update Posted: January 12, 2021
Last Verified: January 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Acute Kidney Injury
Renal Insufficiency
Kidney Diseases
Urologic Diseases